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We previously published analyses of average health care expenditures during 2008 for US 
males with haemophilia. We reported that average annual health-care expenditures were 
$100 000 to $155 000 in 2008 US dollars [1,2]. In this research letter, we report further 
analyses from the MarketScan® research databases intended to help understand differences 
in expenditures for those covered by either Medicaid or employer-sponsored insurance 
(ESI).
Our primary measures of healthcare utilization are proportion of admission, proportion of 
treat-and-release ED visits (hereafter referred to as ED visits), length of hospital stays, 
frequency of ED visits and frequency of non-ED outpatient visits. Length of stay for 
hospitalizations is determined from admission and discharge dates. ED visits that resulted in 
hospital admission are recorded as hospitalizations. Outpatient visits are defined as visits 
based on outpatient claims data, except ED visits and claims filed by laboratories, imaging 
centres, radiologists, pathologists, pharmacists, supply centres, case managers and home 
health-care services.
Propensity score matching method
We use propensity score matching (PSM) technique, which controls for observable 
differences and assumes that unobservable factors are highly correlated with observable 
characteristics [3]. Using a logistic regression model, we estimated the propensity score of 
having Medicaid coverage for all individuals based on a set of observed covariates, without 
interactions or nonlinear terms. Matching covariates were age, risk score, haemophilia A vs. 
B, receipt of bypassing agents, and presence of any predefined comorbid conditions 
(infection with HIV or hepatitis C virus, injury, cardiovascular disease, hypertension, 
hypercholesterolaemia, chronic arthropathy, diabetes, renal disease, musculoskeletal and 
connective tissue issues, intracranial haemorrhage, depression, pulmonary disease, 
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neurological disease or liver disease). All persons with Medicaid coverage were then 
matched to persons with ESI, using the nearest neighbour one-to-one matching technique 
within a calliper of 0.25 standard deviations of the propensity scores [4].
Multivariate model
We conducted multivariate analyses using the propensity score-matched sample. To better 
capture heterogeneous health-seeking behaviours between non-users and users or between 
less and more extensive users, we used mixture models. To assess the influence of covariates 
on outpatient visits and annual expenditures, we employed a semi-parametric, latent-class 
finite mixture model (FMM). Such a model uses observed data on healthcare use to 
distinguish two population subgroups with less vs. more extensive use of healthcare services 
[5,6]. FMM models assign observations into one of two latent classes and estimate both the 
distribution between classes and the ‘effect’ of each class on the amount of service used. The 
latent classes differ for each outcome measure; more extensive users of outpatient services 
are not necessarily more extensive users of annual healthcare expenditures.
To examine predictors of expenditures for clotting factor obtained through pharmacies and 
visits to EDs, we also used a two-part model [7,8], as well as a zero-inflated negative 
binomial model for hospitalization. Both models allow zero and positive values of factor 
expenses from pharmacies and acute care service use. The first part of each predicts factor 
purchasing activity through pharmacies or acute service use as a dichotomy (none vs. some); 
the second part predicts their factor expenditures as a continuous variable, or level of acute 
service use as a count variable conditioned on positive observations.
Results
The final study sample consisted of 419 males with Medicaid and 419 males with ESI who 
were successfully matched using PSM.
Approximately 54% of the sample had zero ED visits and 83% had no hospitalizations 
during 2008 (Table 1). In contrast, only 3% of the sample had no outpatient visits or zero 
annual expenditure recorded. Expenditures per ED visit, outpatient visit and inpatient 
admission among Medicaid enrolees were three-to six-fold lower than among ESI enrolees.
Expenditures per ED visit, outpatient visit and inpatient admission among Medicaid enrolees 
were three-to six-fold lower than among ESI enrolees (Table 1). Medicaid enrolees were less 
than one-half as likely to receive an infusion at home by a health service provider, and 
among those who did, average expenditure on clotting factor per infusion was 35% lower 
(Table 1). Expenditures per unit of clotting factor purchased from pharmacies, identified by 
NDC, were the same for Medicaid and ESI enrolees.
Variables associated with healthcare expenditures and utilization
Regression results are shown in Table 2. In order, dependent variables are (i) total healthcare 
expenditures; (ii) ratio of persons obtaining factor through pharmacies and these 
expenditures for factor if any; (iii) number of outpatient visits; (iv) ratio of persons who had 
Guh et al. Page 2













at least one ED visit and number of ED visits if any and (v) ratio of persons hospitalized and 
annual length of stay, if any.
The coefficients of the first two rows of each model in Table 2 measure the associations of 
Medicaid coverage with healthcare expenditures and utilization, relative to employer-
sponsored insurance (default), by Medicaid qualification criteria (poverty or disability). 
Total expenditures differed by Medicaid qualification criteria and level of healthcare use 
(less vs. more extensive users, see columns 2–3). The FMM identified 87% of the study 
sample as less extensive users and 13% as more extensive users of overall healthcare 
resources. Total expenditures of poverty-qualified Medicaid enrolees were lower than those 
of ESI enrolees, whereas disability-qualified Medicaid enrolees had significantly higher total 
expenditures.
Medicaid enrolees were more likely to obtain factor through pharmacies, regardless of 
Medicaid qualification criteria, than ESI enrolees (P < 0.01, see column 4). However, their 
expenditures for factor differed by Medicaid qualification criteria, compared to those of ESI 
enrolees (see column 5). The factor expenditures of poverty-qualified Medicaid enrolees 
among those who had positive pharmacy expenditures were significantly lower than those of 
ESI enrolees (P < 0.01), whereas those of disability-qualified Medicaid enrolees had a 
coefficient close to zero, i.e., essentially the same as the ESI group.
The difference in frequency of outpatient visits between Medicaid enrolees and ESI enrolees 
varied by level of healthcare use (columns 6–7). Among more extensive users, Medicaid 
enrolees had significantly more frequent outpatient visits than ESI enrolees. In contrast, 
among less extensive users, there was no significant difference in the frequency of outpatient 
visits between insurance types.
A higher proportion of poverty-qualified Medicaid enrolees than those with ESI had at least 
one ED visit (column 8). Among ED users, Medicaid enrolees had more frequent ED visits 
than those with ESI, regardless of Medicaid eligibility criteria (column 9). The proportion of 
Medicaid enrolees receiving inpatient care services was slightly lower, but the difference 
was not statistically significant (column 10). When disability-qualified Medicaid enrolees 
were admitted to hospitals, they were likely to stay significantly longer than those with ESI 
(column 11).
Comorbidities such as injury, hypertension, chronic arthropathy, intracranial haemorrhage 
and depression were significant cost drivers. Injury, intracranial haemorrhage and depression 
were also associated with increased healthcare utilization, especially more frequent 
outpatient visits and ED visits and longer hospitalizations. Although other comorbidities 
such as musculoskeletal, connective tissue and neurological disease were associated with the 
likelihood and frequency of ED visits and outpatient visits, especially among less extensive 
users, they were not statistically significant cost drivers. Also, these comorbidities were not 
associated with use of inpatient care.
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We found that Medicaid spends less on average than ESI plans for males with haemophilia 
on a health risk-adjusted basis, by an average of $17 277 per person per year, in 2008 
dollars. A novel contribution of this study is the use of a latent-class regression model. Such 
a model can better capture heterogeneous behaviours between less and more extensive users. 
Lower expenditures associated with Medicaid coverage were concentrated among less 
extensive users, whose healthcare expenditures were relatively moderate. In contrast, 
predicted Medicaid spending was higher than ESI spending among extensive users of 
healthcare services (average expenditures of more than half a million dollars per year).
Slightly lower predicted spending through Medicaid than ESI reflects a combination of 
marginally higher utilization and much lower average expenditure per service. We found that 
Medicaid enrolees with haemophilia had (i) more frequent outpatient visits among more 
extensive users; (ii) higher likelihood of ED visits among poverty-qualified Medicaid 
enrolees; (iii) more frequent ED visits regardless of Medicaid qualification and (iv) more 
hospital days among disability-qualified Medicaid enrolees.
Differences in the severity of haemophilia symptoms can explain the observed differences in 
utilization between the two Medicaid eligibility groups, since the poverty-qualified enrolees 
showed lower demand for clotting factor and inpatient care. The positive association of 
poverty-qualified Medicaid coverage with ED use (relative to ESI) is consistent with reports 
of increases in ED visits among newly insured individuals with Medicaid [10,11].
Most of the limitations of this study are inherent in claims data: non-representativeness at 
the population level, lack of data on socioeconomic status, under-ascertainment of those 
with mild symptoms and understatement of expenditures for people with coverage by other 
insurance plans. We were not able to classify individuals as having severe, moderate or mild 
haemophilia due to lack of clinical data.
In conclusion, insurance type affected patients’ source of factor; healthcare utilization varied 
by Medicaid qualification criteria and by extensiveness of service use. On average, because 
of lower reimbursements, Medicaid spent less per person with haemophilia than did ESI 
plans. However, Medicaid spent more on extensive users than did ESI plans.
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Table 1
Descriptive statistics of healthcare expenditures and utilization using the study sample selected after 





Annual healthcare expenditures ($)
 Annual expenditures‡ 156 235   122 883*
 Annual expenditures for clotting factor‡ 132 346   115 151
Factor obtained through pharmacies (identified by NDC)
 Proportion of people (%)§   28      72***
 Expenditures for factor ($) ≥ 0‡ 38 160     90 495***
Healthcare utilization
 Proportion of people with ≥1 ED visits (%)§   41.3       50.8***    
 Number of ED visits with ≥1 visits‡    3.5      3.3    
 Proportion of people with ≥1 admissions (%)§   15.3      19.6*    
 Number of inpatient admission with ≥1 admissions‡    1.6      2.0     
 Annual length of stay with ≥1 admissions‡    8.0      9.1    
 Proportion of people with ≥1 outpatient visits (%)§   99.0      99.0    
 Number of outpatient visits with ≥1 visits‡   10.8      11.0    
 Proportion of people receiving factor at home (%)$   80.9      85.2    
  Infusion, identified by procedure codes   56.1       22.7***     
  Infusion, identified by NDCs   29.8      76.1*** 
Expenditure per service ($) > 0
 Expenditure for factor per infusion (identified by procedure code)‡ 20 806    13 595***
 Expenditure for factor per unit (identified by NDC)¶,‡     1.50      1.50   
 Expenditure per ED visit‡   782      213***  
 Expenditure per outpatient visit‡  1246      223***  
 Expenditure per hospital day‡ 13 264     2442***  
 Expenditure per admission‡ 73 764    25 686***  
†






Excluding Stimate nasal spray the symbols ***, **, and * indicate a significance level of 1%, 5%, and 10%, respectively, for a two-tailed test.
ESI, employer-sponsored insurance; ED, Emergency Department; NDC, National Drug Code.
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